This article is more than 5 years old. Information may no longer be current.
Certolizumab pegol pen now available in UK
Click Here to Manage Email Alerts
Following a positive opinion by a European Medicine Agency committee, the certolizumab pegol autoclicks prefilled pen is now available on the United Kingdom’s National Health Service, according to a UCB press release.
The European Medicine Agency recommended the certolizumab pen (Cimzia, UCB) — which was also co-developed by OXO and Bespak — for all previously approved conditions: rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis and axial spondyloarthritis. The pen provides a button-free delivery system and a no-slip grip in order to help patients with hand disabilities. In addition, the pen has a viewing window that displays the progress of injection.
For the two treatment doses of 200 mg required each month, the pen will cost £715 to the National Health Service.
“It is difficult for people who do not suffer from this disease to understand how challenging doing the ordinary things in daily life can be, more so for those with painful and swollen joints,” Alisa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said in the release. “Trying to grip an everyday object, such as a kitchen gadget, can cause immense pain. So, we welcome any innovation that can help make the lives of RA patients more comfortable while they manage their condition.”
Reference: